Advanced treatment process for pharmaceuticals, endocrine disruptors, and flame retardants removal
The objective of this project was to demonstrate the effectiveness of an advanced treatment process that did not utilize reverse osmosis for the removal of pharmaceuticals, endocrine disruptors and flame retardants (collectively referred as contaminants of emerging concern [CECs]) from municipal eff...
Veröffentlicht in: | Water environment research : a research publication of the Water Environment Federation. - 1998. - 86(2014), 2 vom: 30. Feb., Seite 111-22 |
---|---|
1. Verfasser: | |
Weitere Verfasser: | , |
Format: | Aufsatz |
Sprache: | English |
Veröffentlicht: |
2014
|
Zugriff auf das übergeordnete Werk: | Water environment research : a research publication of the Water Environment Federation |
Schlagworte: | Journal Article Research Support, Non-U.S. Gov't Endocrine Disruptors Flame Retardants Water Pollutants, Chemical Charcoal 16291-96-6 Ozone 66H7ZZK23N |
Zusammenfassung: | The objective of this project was to demonstrate the effectiveness of an advanced treatment process that did not utilize reverse osmosis for the removal of pharmaceuticals, endocrine disruptors and flame retardants (collectively referred as contaminants of emerging concern [CECs]) from municipal effluent. The advanced treatment process consisted of (in the order of use): membrane filtration, ozonation (O3), and biologically active carbon (BAC) filtration. Ozone dosage of 5 mg/L or more was needed for desired CEC removal. Biologically active carbon removed flame retardants, and ozonation byproducts including NDMA and aldehydes. The project successfully demonstrated 1) the removal of a wide range of CECs, 2) reduction of estrogen activity to background levels, and 3) removal of ozonation byproducts. Treatment was achieved at lower costs and power utilization than reverse osmosis and without generating a concentrate stream. Results from this project could make CEC removal feasible, especially in situations where reverse osmosis treatment is infeasible |
---|---|
Beschreibung: | Date Completed 08.04.2014 Date Revised 23.09.2019 published: Print Citation Status MEDLINE |
ISSN: | 1554-7531 |